Closed
The Marked Chart Wire · Health
Bristol Myers Squibb
Bristol Myers Squibb announced that its cancer treatment doubled the time patients lived without disease progression. The drug also showed promising results in other solid tumors.
New to this? Read: Reading a stock chart
Enhertu
AstraZeneca paid a $75 million milestone to Daiichi Sankyo following European Union approval of the therapy for early-stage HER2-positive breast cancer. Trial results showed a 53 percent reduction in recurrence or death risk compared to T-DM1.
Weight-Loss Drugs
A court rejected Novo Nordisk's legal effort to stop Eli Lilly from advertising its weight-loss medications, clearing the way for the company to continue its marketing campaign.
PACIFIC-9
AstraZeneca updated the timeline for its PACIFIC-9 phase 3 trial in non-small cell lung cancer, moving the data readout from the second half of 2026 to the first half of 2027. Enrollment for the study is complete.
Moderna
The biotech executive stated that the current melanoma vaccine is anticipated to show efficacy against additional types of malignancy.
Pfizer
The U.S. Food and Drug Administration approved Pfizer's TALZENNA in combination with XTANDI for specific prostate cancer patients.
Keytruda
Merck reported that its Phase 3 study achieved its main objective. Keytruda alone cut the chance of disease worsening or patient mortality by 43 percent relative to standard chemotherapy for specific advanced cases.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.